Dynamics of markers of hepatic fibrosis on therapy liraglutide at patients with type 2 diabetes mellitus in combination with a metabolic syndrome
https://doi.org/10.31146/1682-8658-ecg-157-9-86-94
Abstract
Therapy of glucagon-like peptide 1 receptors agonists (aGLP1) liraglutide within 24 weeks led to considerable weight reduction, a circle of a waist, HbA1c, TG, AST and increase in HDLP at patients with type 2 diabetes mellitus (2TDM) and multiple manifestations of metabolic syndrome (obesity, dyslipidemia, hypertension) in real clinical practice. Effects of therapy liraglutide on the markers of fibrosis and a scale estimating risk of its progression were ambiguous and depended on various predictors. Decrease in the index of fibrosis on therapy aGLP1 depended on a floor and extent of increase in HDLP. Dynamics galectin-3 depended on weight reduction and its significant decrease is noted only at patients with loss weight ≥ 5%. Initial levels of incretin (GIP and GLP1) acted as predictors of decrease in PIIINP. Further researches on big cohorts of patients with obesity, a metabolic syndrome and 2TDM are necessary for definition of groups of the patients capable it is essential to reduce risk of a progression of fibrosis on therapy aGLP1
Keywords
Неалкогольная жировая болезнь печени,
ожирение,
адипоцитокины,
лептин,
адипонектин,
глюкагоноподобный пептид-1,
грелин,
инкретиномиметики,
галектин-3,
маркеры фиброза,
агонисты рецепторов глюкагоноподобного пептида-1,
Non-alcoholic fatty liver disease,
obesity,
adipocytokines,
leptin,
adiponectin,
glucagon-like peptide-1,
ghrelin,
incretinomimetics,
markers of fibrosis: glucagon-like peptide-1 receptors agonists,
galectin-3,
markers of fibrosis: glucagon-like peptide-1 receptors agonists,
сахарный диабет 2 типа,
type 2 diabetes mellitus,
type 2 diabetes mellitus
About the Authors
A. Yu. Babenko
Federal State Budgetary Institution “Almazov National Medical Research Centre” of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
M. Yu. Laevskaya
Federal State Budgetary Institution “Almazov National Medical Research Centre” of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
A. Yu. Trofimova
Federal State Budgetary Institution “Almazov National Medical Research Centre” of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
A. V. Simanenkova
Federal State Budgetary Educational Institution of Higher Education “Academician I.P. Pavlov First St. Petersburg State Medical University” of the Ministry of Healthcare of Russian Federation
Russian Federation
Russian Federation
A. A. Mosikian
Federal State Budgetary Institution “Almazov National Medical Research Centre” of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
E. Yu. Vasilieva
Federal State Budgetary Institution “Almazov National Medical Research Centre” of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
E. V. Shlyakhto
Federal State Budgetary Institution “Almazov National Medical Research Centre” of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Review
For citations:
Babenko A.Yu., Laevskaya M.Yu., Trofimova A.Yu., Simanenkova A.V., Mosikian A.A., Vasilieva E.Yu., Shlyakhto E.V. Dynamics of markers of hepatic fibrosis on therapy liraglutide at patients with type 2 diabetes mellitus in combination with a metabolic syndrome. Experimental and Clinical Gastroenterology. 2018;(9):86-94. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-157-9-86-94
Views:
463
Email this article 